Obermatt
See Similar Stocks →

Cellectis

PAR:ALCLS · FR0010425595
BiotechnologySmall

360

19
Profit price71
Owner Earnings Yield1
Dividend Yield1
Price/Sales76
EV / Gross Profit61
Price/Book95
Return on Capital75
Cash Return on Capital25
Return on Equity26
EBIT Margin28
Gross Profitability78
Accruals34
Owner Earnings Margin60
Sales growth16
Profit growth28
Reinvestment23
Price momentum85
Debt load28
Refinancing4
Debt Payback1
Liquidity46
Analyst ratings100
Opinion Changes50
Price Target Upside51
Market mood49
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Cellectis doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryFrance
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeENXTPA
Founded2000
Employees223
Websitecellectis.com
ISINFR0010425595
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
HematologyImmunologyStem Cell TherapyGeneticsOncologyBiopharmaBiotechnologyMedical

Description

Cellectis S.A. operates as a clinical stage biotechnological company. The company is employing its core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or Universa…

Analysis

Middle-of-the-road

Cellectis S.A. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is fragile. The company scores 6/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
57
2026

All-time high

57

Jun 2026

All-time low

22

Mar 2026

Average rank

40

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
76
—
—
—
Price/Earnings
37
—
—
—
Price/Book
95
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
87
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Cellectis with its peers
BioNTech
NSQ:BNTX
11
CountryGermany
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Inventiva
PAR:IVA
16
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Compugen
NAQ:CGEN
19
CountryIsrael
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Galapagos
AEX:GLPG
76
CountryBelgium
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Roivant Sciences
NSQ:ROIV
47
CountryUK
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
CRISPR Therapeutics
NMQ:CRSP
22
CountrySwitzerland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →